Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: bifeprunox

• Registration Number: NCT00581451
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

Safety and tolerability study in healthy volunteers

Detailed Description

Not available

Study Timeline

• Study Start: 2007-10
• Study First Submitted: 2007-12-21
• Study First Submitted QC: 2007-12-26
• Study First Posted: 2007-12-27
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Status Verified: 2009-07
• Last Update Submitted: 2009-07-08
• Last Update Posted: 2009-07-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
C	bifeprunox	bifeprunox 14 day
D	bifeprunox	bifeprunox 9 day
A	bifeprunox	bifeprunox 25 day
B	bifeprunox	bifeprunox 14 day

Primary Outcome Measures

Name	Time	Method
Tolerability	28 days

Secondary Outcome Measures

Name	Time	Method
Safety	28 days